The Use of Cytokines, Tumor Infiltrating Lymphocytes, and Gene Therapy in the Treatment of Advanced Renal Cell Carcinoma: The UCLA Experience

  • Arie Belldegrun
  • Kambiz Dardashti
  • Cho-Lea Tso
  • Randhir Kaboo
  • Samir Taneja
  • Jean B. deKernion
  • Robert Figlin
Conference paper

Abstract

The approach to disseminated renal cell carcinoma (RCC) has evolved significantly in the past decade, largely due to availability and efficacy of biologic therapy. Since Rosenberg first reported the use of Interleukin 2 (IL-2) and lymphokine activated killer cells (LAK) in advanced RCC1, numerous combinations of cytokines and lymphoid cells have been used in treatment of RCC with varying success. Currently, high dose IL-2 remains the only FDA approved agent for biologic therapy of RCC. However, most renal cell carcinoma patients fail to benefit from IL-2 and toxicity when administered in high dose bolus fashion is considerable. In an effort to improve response rate and decrease toxicity, we have employed the use of combination low dose IL-2 and IFNα with and without ex vivo expanded tumor infiltrating lymphocytes (TIL). We are also investigating the potential utility of gene therapy for development of a tumor vaccine, as well as target directed cytokine delivery. This chapter summarizes some or our experiences with cytokine therapy, adoptive immune therapy with TIL, and gene therapy.

Keywords

Toxicity Adenocarcinoma Oncol Interferon Laminin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high-dose bolus interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Gitlitz B, Pierce W, Moldawer N, deKernion J, Belldegrun A, Figlin R: Long term follow-up and patterns of relapse in metastatic renal cell carcinoma (RCCa) using an outpatient regimen of low dose Interleukin-2 (IL-2) and Interferon-alpha (IFN): UCLA Kidney Cancer Program. Pron. ASCO 1994 13: 254.Google Scholar
  3. 3.
    Rosenberg SA, Yang UC, Topalian SL, Schwartzentruber DJ, Weyer JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2.Google Scholar
  4. 4.
    Belldegrun A, Pierce WC, Kaboo R, Tso CL, Hungyi S, Turcillo P, Moldawer N, Golub S, deKernion J, Figlin R: Interferon alpha primed tumor infiltrating lymphocytes combined with interleukin-2 and interferon-a as a therapy for metastatic renal cell carcinoma. J ofUrol 1993, 150: 1384–1390.Google Scholar
  5. 5.
    Belldegrun A, Pierce W, deKernion J, Kaboo R, Okarma T, Figlin R: Clinical activity of purified CD8+ tumor infiltrating lymphocytes and low dose IL-2 in the treatment of metastatic renal cell carcinoma. J of Urol 1994; 151: 352a.Google Scholar
  6. 6.
    Figlin RA, Belldegrun A, Moldawer N, deKernion JB: Concomitant administration of recombinant human interleukin-2 and recombinant interferon α-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992: 10: 414–21.PubMedGoogle Scholar
  7. 7.
    Pierce WC, Belldegrun A, Figlin R: Cellular therapy: Scientific rationale and clinical results in the treatment of metastatic renal cell carcinoma. Sem Oncol 1994; in press.Google Scholar
  8. 8.
    Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310–13.PubMedGoogle Scholar
  9. 9.
    Steger G, Pierce W, Figlin R, Czernin J, Kaboo R, deKernion J, Okarma C, Belldegrun A: Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor infiltrating lymphocytes. Clin Immunol and Immunopathology 1994; 72 (2): 237–247.CrossRefGoogle Scholar
  10. 10.
    Colombo MP, Ferrati G, Stoppacciaro A: Granulocyte colony stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Asher AL, Mule JJ, Kasid A: Murine tumor cells transduced with the gene for tumor necrosis factor-a. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991; 146: 3227–3234.PubMedGoogle Scholar
  12. 12.
    Belldegrun A, Tso CL, Sakata T, Duckett T, Brunda MJ, Barsky SH, Chai J, Kaboo R, Lavey RS, McBride WH, deKernion JB: Human renal carcinoma line transfected with interleukin-2 and/or interferon a gene(s): Implications for live cancer vaccines. J Natl Cancer Inst 1993 85: 207–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Hathorn RW, Tso CL, Kaboo R, Pang S, Figlin R, Sawyers C,deKernion J, Belldegrun A: Transduction of IL-2 or/and IFN-α gene(s) abrogates invasive and metastatic potential of human renal cancer. Cancer Gene Therapy In press.Google Scholar
  14. 14.
    Miller AR, Skotzko MJ, Rhoades K, Belldegrun AS, Tso CL, Kaboo R, McBride WH, Jacobs E, Kohn DB, Moen R, Economou JS: Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications. Hum Gene Ther 1992: 3: 619–624.PubMedCrossRefGoogle Scholar
  15. 15.
    Pockau BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo JA, Steinberg SM, Resenberg SA, Yang JC: Localization of 11 llndium-labeled tumor infiltrating Iymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 1994; 73: 1731–37.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1995

Authors and Affiliations

  • Arie Belldegrun
    • 1
  • Kambiz Dardashti
    • 1
  • Cho-Lea Tso
    • 1
  • Randhir Kaboo
    • 1
  • Samir Taneja
    • 1
  • Jean B. deKernion
    • 1
  • Robert Figlin
    • 1
  1. 1.The UCLA Kidney Cancer Program Division of UrologyDepartment of Surgery UCLA School of MedicineUSA

Personalised recommendations